Supplemention with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats

Hong Jye Hong, George Hsiao, Tzu Hurng Cheng, Mao Hsiung Yen

研究成果: 雜誌貢獻文章

163 引文 斯高帕斯(Scopus)

摘要

It has been suggested that tetrahydrobiopterin (H4B), a cofactor of NO synthase, can reverse endothelial dysfunction caused by cardiovascular diseases, including atherosclerosis, coronary artery disease, and hypertension. Moreover, an impairment of H4B biosynthesis in spontaneously hypertensive rats (SHR) was observed. Thus, we hypothesized that the defect of the H4B synthesis system may play an important role in the development of hypertension in SHR. In the present study H4B (10 mg/kg per day IP) was used to treat SHR and Wistar-Kyoto rats (WKY) from the age of 5 through 16 weeks. Results demonstrated that chronic treatment with H4B significantly improved the impaired vascular responses to acetylcholine and suppressed the development of hypertension in SHR but did not affect WKY. The increase of inducible NO synthase expression, nitrotyrosine immunostaining, NO production, and superoxide anion formation in adult SHR were also significantly suppressed by chronic treatment with H4B. In contrast, H4B had no effect on WKY. In conclusion, this study demonstrated that H4B significantly attenuated the development of hypertension in SHR. The antihypertensive effect of H4B might be mediated through its direct antioxidant activity and/or decreasing oxygen free radical production from NO synthase, thereby reducing inducible NO synthase expression and peroxynitrite formation. Thus, the present study proposed that supplementation with H4B might be beneficial in preventing pathological conditions such as essential hypertension.
原文英語
頁(從 - 到)1044-1048
頁數5
期刊Hypertension
38
發行號5
出版狀態已發佈 - 2001
對外發佈Yes

ASJC Scopus subject areas

  • Internal Medicine

指紋 深入研究「Supplemention with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats」主題。共同形成了獨特的指紋。

  • 引用此